Lamesa Tolera Ambisa
School of Medical Laboratory Science, Jimma University, Jimma, Ethiopia.
HIV AIDS (Auckl). 2024 Apr 3;16:123-132. doi: 10.2147/HIV.S445605. eCollection 2024.
Lipodystrophy syndrome is a medical condition characterized by the absence of adipose tissue without any underlying starvation or macromolecule breakdown. In HIV AIDS patients, the use of highly active antiretroviral therapy (HAART) can lead to an acquired form of lipodystrophy, with a prevalence ranging from 10% to 83% among HIV AIDS patients. It was aimed to review the current understanding of biological depiction and challenges related to lipodystrophy in AIDS patients. Relevant articles published in the English language were searched in PubMed, Google Scholar, and Google. Keywords used for the search were: lipodystrophy, lipodystrophy and HIV, ART and lipodystrophy, HIV treatment, metabolic syndrome and HIV. Articles with full abstract information were read for those that met the objective criteria of the review, then full text of the articles was accessed and used. It was revealed by the literature that patients who developed lipodystrophy are characterized by insulin abnormality, obesity, diabetes mellitus, dyslipidemia, fatty liver disease, and ovarian dysfunction. Anthropometric measurements have been known to change significantly with lipodystrophy. HIV patients suffering from hepatitis C virus, hepatitis B virus, who take a protease inhibitor, are changing treatment or duration of treatment, and are women are the common risk factors for lipodystrophy. The metabolic syndrome seen in HIV patients associated with lipodystrophy can further be complicated to different adverse health effects and can result in increased morbidity and mortality rate if not treated. Existing studies have successfully identified several challenges faced by HIV AIDS patients due to lipodystrophy, including low self-esteem, compromised quality of life, and poor treatment adherence. However, it is crucial to acknowledge that there may be numerous other challenges that have yet to be discovered, emphasizing the need for further studies. It is recommended that managing dyslipidemia, treating diabetes mellitus, modifying lifestyle, and improving the anthropometric measurements have crucial roles to halt further complications associated with lipodystrophy.
脂肪营养不良综合征是一种医学病症,其特征是不存在脂肪组织,且没有任何潜在的饥饿或大分子分解情况。在艾滋病毒/艾滋病患者中,使用高效抗逆转录病毒疗法(HAART)可导致获得性脂肪营养不良,在艾滋病毒/艾滋病患者中的患病率为10%至83%。本文旨在综述目前对艾滋病患者脂肪营养不良的生物学描述及相关挑战的认识。在PubMed、谷歌学术和谷歌中检索了以英文发表的相关文章。搜索使用的关键词为:脂肪营养不良、脂肪营养不良与艾滋病毒、抗逆转录病毒疗法与脂肪营养不良、艾滋病毒治疗、代谢综合征与艾滋病毒。对符合综述目标标准的文章阅读其完整摘要信息,然后获取并使用文章全文。文献显示,发生脂肪营养不良的患者具有胰岛素异常、肥胖、糖尿病、血脂异常、脂肪肝疾病和卵巢功能障碍等特征。已知人体测量学指标会因脂肪营养不良而发生显著变化。感染丙型肝炎病毒、乙型肝炎病毒、服用蛋白酶抑制剂、正在改变治疗方案或治疗时长的艾滋病毒患者以及女性是脂肪营养不良的常见危险因素。艾滋病毒患者中与脂肪营养不良相关的代谢综合征可能会进一步引发不同的不良健康影响,如果不进行治疗,可能会导致发病率和死亡率上升。现有研究已成功识别出艾滋病毒/艾滋病患者因脂肪营养不良面临的若干挑战,包括自卑、生活质量受损和治疗依从性差。然而,必须认识到可能还有许多其他尚未发现的挑战,这凸显了进一步研究的必要性。建议管理血脂异常、治疗糖尿病、改变生活方式以及改善人体测量学指标对于阻止与脂肪营养不良相关的进一步并发症至关重要。